TEMENOS
29.4.2020 08:32:10 CEST | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced the launch of eight propositions – using innovative Explainable AI (XAI) and cloud technologies – to help banks in their immediate response to the Covid-19 crisis. Temenos is supporting banks to ensure business continuity, enhance digital engagement to meet clients’ changing needs, and manage socioeconomic pressures. These Covid-19 propositions are immediately available worldwide. Delivered as Temenos SaaS, they are deployed quickly, easily and can be implemented remotely, if required.
Temenos is bringing together its dynamic community at Temenos Community Forum Online on 29-30 April to explore ‘Solutions for the New Normal’. Over 5,000 attendees have registered for the action-packed, virtual summit, with 43 product announcements, 49 live Q&A sessions with Temenos experts and over 30 demos showing Temenos’ latest innovations from cloud to digital engagement technologies and Explainable AI. At TCF Online Temenos will showcase how its solutions are addressing the fast-growing needs for digitalization, personalization and greater agility, solving the immediate Covid-19 challenges and creating sustainable business models for the future.
Max Chuard, Chief Executive Officer, Temenos, said: “I am proud of the AI and cloud-advanced propositions we have delivered to help banks address their most pressing needs during Covid-19. I am also proud of our family of Temenos employees, who have worked tirelessly to make this response a reality. As the leader in banking software, we are relentlessly investing in R&D to keep banks running as they assist SMEs, corporate and retail customers at a time of financial distress. In the ‘New Normal’, the need for modern digital banking will be greater than ever. Only Temenos can provide banks the richest banking functionality and the most advanced cloud-native technology to help them deliver value to their customers and build sustainable growth in the future.”
To support banks, Temenos launched the following AI-driven SaaS technology propositions which are immediately available to help banks with the Covid-19 crisis:
- Enhancing customer digital interactions – With the surge in digital banking volumes Temenos is helping banks meet customers’ needs for intimate digital interactions, particularly those who typically bank in branches. Temenos Infinity Engage gives customers a personal digital communications channel to connect with their trusted advisors within the bank.
- Helping banks give financial relief to SMEs and retail customers with Explainable AI (XAI) – Temenos’ new XAI models delivered as SaaS help banks assist small businesses and retail customers with fast loan approval and viable financial products. These XAI models delivered as SaaS will help banks digitally on-board, conduct eligibility checks, process loan applications and establish the right product pricing. These models include Temenos AI - Urgent Relief Loan, Temenos AI-Personalization and Temenos AI – SME Smart Decisioning.
- US Paycheck Protection Program quick roll out – Temenos is helping US banks and credit unions with Temenos Infinity, the digital omnichannel product, to rapidly process loan applications from small businesses under the US government’s PPP and give them the funding they need. Temenos working together as one team with Atlantic Union Bank helped the bank build a brand new digital loan portal specifically for PPP in less than a week.
- Rapidly adapt AML, KYC and fraud management to new emerging threats – Temenos has partnered with Microsoft to offer fast access to its AI-driven, Temenos Financial Crime Mitigation SaaS solution to help banks combat the rise in cybercrime due to Covid-19. Temenos has proven its ability to support banks of all sizes without disruption, providing comprehensive AML/KYC/fraud management while all bank employees are working remotely.
- Helping banks rapidly launch or adapt products to respond to Covid-19 – Governments and regulators are asking banks to make product changes, such as payments holidays and loan restructurings. Temenos Continuous Deployment delivered as Temenos SaaS supports banks to accelerate changes in test and live environments, providing remote, automated, secure DevOps tools. This means that all necessary product changes can take place in these fast changing, and resource constrained times.
- Providing training opportunities for bank employees – Temenos opened its online learning platform with over 400 courses for all Temenos products and sandboxes for free to allow bank users to experience and test Temenos’ latest technology innovations from their own home. More than 3,000 banking practitioners have registered to increase their knowledge on Temenos products and upskill team members. To request free access by visit here .
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200428005713/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
